Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Public ClinicalTrials.gov record NCT01439282. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Study identification
- NCT ID
- NCT01439282
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eisai Inc.
- Industry
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Interventions
- eribulin mesylate Drug
- capecitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2011
- Primary completion
- Oct 31, 2012
- Completion
- Apr 30, 2014
- Last update posted
- Jun 21, 2023
2011 – 2014
United States locations
- U.S. sites
- 23
- U.S. states
- 8
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC - HOPE | Tucson | Arizona | 85704 | — |
| Arizona Oncology Associates, PC - CASA | Tucson | Arizona | 85715 | — |
| Cancer Centers of Florida | Orlando | Florida | 32806 | — |
| Northwest Georgia Oncology Centers, P.C. | Marietta | Georgia | 30060 | — |
| New York Oncology Hematology, P.C. | Albany | New York | 12206 | — |
| Sciode Medical Associates, PLLC, d.b.a. Eastchester Center | The Bronx | New York | 10469 | — |
| Cancer Centers of the Carolinas | Greenville | South Carolina | 29605 | — |
| Texas Oncology-Austin Central | Austin | Texas | 78731 | — |
| Texas Oncology-Medical City Dallas | Dallas | Texas | 75230 | — |
| Texas Oncology-Dallas Presbyterian Hospital | Dallas | Texas | 75231 | — |
| Texas Oncology-Methodist Charlton Cancer Center | Dallas | Texas | 75237 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology- Denton South | Denton | Texas | 76210 | — |
| Texas Oncology-Fort Worth 12th Ave. | Fort Worth | Texas | 76104 | — |
| Texas Oncology-Memorial City | Houston | Texas | 77024 | — |
| Texas Oncology-Lewisville | Lewisville | Texas | 75067 | — |
| Texas Oncology-Paris | Paris | Texas | 75460 | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | 78217 | — |
| Texas Oncology-Tyler | Tyler | Texas | 75702 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Evergreen Hematology and Oncology | Spokane | Washington | 99218 | — |
| Northwest Cancer Specialists, P.C. | Vancouver | Washington | 98684 | — |
| Yakima Valley Memorial Hospital/North Star Lodge | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01439282, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01439282 live on ClinicalTrials.gov.